Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupDVHGF 49 Receivables Turnover is 0.57 as of Apr. 2026. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $1.99 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, Devonian Health Group ranks worse than 84.42% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Devonian Health Group's Revenue for the
three
months ended in Apr. 2026 was $0.13 Mil. Devonian Health Group's average Accounts Receivable for the
three
months ended in Apr. 2026 was $0.23 Mil.
Hence, Devonian Health Group's Receivables Turnover for the
three
months ended in Apr. 2026 was 0.57.
Devonian Health Group (OTCPK:DVHGF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Devonian Health Group Receivables Turnover Related Terms
Devonian Health Group Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVHGF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Devonian Health Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (DVHGF) has a Receivables Turnover of 0.57 as of Apr. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #710 out of 841 companies in the Biotechnology industry, placing it in the top 84.4%.
Is Devonian Health Group's Receivables Turnover too high?
Devonian Health Group's current Receivables Turnover is 0.57. The Biotechnology industry median Receivables Turnover is 5.29. Devonian Health Group's value of 0.57 is 89.2% below this industry median. Based on the distribution chart, Devonian Health Group ranks #710 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #710 out of 841 companies for Receivables Turnover. This places Devonian Health Group in the lower half of its industry. The industry median Receivables Turnover is 5.29. Devonian Health Group's value of 0.57 is 89.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Devonian Health Group's current Receivables Turnover of 0.57 is 89.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Devonian Health Group and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current Receivables Turnover is 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.99, compared to a current price of $7.00 — trading 251.8% above its estimated fair value. The current Receivables Turnover is 0.57 and 89.2% below the Biotechnology industry median of 5.29. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Receivables Turnover is 0.57 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 251.8% above its estimated GF Value™ of $1.99.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
Receivables Turnover: 0.57
GF Value™: $1.99 vs. price of $7.00 (251.8% above fair value)
Industry Position: 89.2% below the Biotechnology median (#710 of 841)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score
Get the complete analysis for DVHGF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
